New research highlights the potential of a multi-pathway approach to treatment
Researchers have reported promising preclinical results for an experimental therapy that could provide a new treatment approach for metabolic dysfunction associated steatohepatitis (MASH), a progressive form of fatty liver disease that can lead to cirrhosis, liver failure and liver transplantation. The therapy reduced liver fat, inflammation, tissue damage and fibrosis in laboratory models, suggesting it may be capable of tackling multiple drivers of disease progression simultaneously.
MASH develops when excess fat accumulates in the liver, triggering chronic inflammation and cellular injury. Over time, these changes can lead to fibrosis, the buildup of scar tissue that may eventually progress to advanced liver disease. Although the first medications for MASH have recently become available, treatment options remain limited and are generally reserved for people with more advanced disease.
The new research, published in JHEP Reports, was led by investigators from the Texas A&M College of Veterinary Medicine & Biomedical Sciences. The researchers identified a protein called MAP4K4 as a potential therapeutic target after finding its activity increased as MASH progressed. Because MAP4K4 is involved in several biological pathways linked to disease development, the team believed it could offer a broader therapeutic target than approaches focused on a single aspect of the disease.
The Texas A&M University researchers, working with collaborators at the University of Oklahoma, evaluated an experimental small molecule inhibitor known as GPPD. Rather than reducing the amount of MAP4K4 present in the body, GPPD selectively inhibits the protein's activity. This approach is intended to preserve the protein's normal biological functions while limiting its contribution to disease progression.
"We have shown in our preclinical model that targeting the MAP4K4 pathway attenuates all of the major hallmarks of MASH," said Dr. Adi Joshi, Associate Professor in the Department of Veterinary Physiology and Pharmacology at the Texas A&M College of Veterinary Medicine & Biomedical Sciences. "That gives us hope that this could eventually become a useful treatment option for patients, especially those who currently have very few therapeutic options."
One of the most noteworthy findings was the breadth of the treatment's effects. Researchers reported improvements across several defining characteristics of MASH, including liver fat accumulation, inflammation, liver injury and fibrosis. This is significant because MASH is increasingly recognised as a complex metabolic disease involving numerous interconnected biological pathways.
Many investigational therapies have focused primarily on reducing fat accumulation in the liver. However, growing evidence suggests that meaningful disease modification may require treatments capable of addressing several pathological processes at once.
"MAP4K4 is a master regulator that influences multiple biological pathways involved in fat accumulation and disease progression," Dr Joshi said. "GPPD is unique because it decreases the protein's activity without changing its overall levels, which may help preserve its normal functions while still providing therapeutic benefit."
The study also helped uncover a previously unknown signalling pathway through which MAP4K4 appears to influence MASH progression. According to the researchers, a better understanding of this pathway could reveal additional therapeutic targets and provide new insights into the biological mechanisms underpinning the disease.
"MASH is a complex metabolic disorder and is orchestrated by alternations in multiple pathophysiological pathways," Dr Joshi said. "It's important to target multiple hallmarks of MASH rather than just one, and GPPD appears to attenuate many of the changes that are elevated during the disease."
The therapy also demonstrated an encouraging safety profile during preclinical testing. Researchers conducted extensive toxicology studies and reported no evidence of significant toxicity to date, an important milestone as the program advances towards clinical development.
Before human trials can begin, the research team is undertaking pharmacokinetic studies to better understand how the compound is absorbed, distributed and processed by the body. Investigators are also exploring whether the benefits observed in preclinical models are directly attributable to the drug's effects on liver disease, the weight loss seen during treatment, or a combination of both.
While significant work remains before the therapy can be tested in patients, the findings add to growing efforts to develop more effective treatments for MASH. If future studies confirm the current results, the therapy may offer a new option for patients whose disease has progressed beyond simple fat accumulation but has not yet reached the most severe stages of liver damage.
"I think it's very important to identify novel targets against this disease," said Dr Joshi. "If the clinical work is successful, I think it will really give hope to millions of patients living with this condition."